Phaseline

Companies › KalVista Pharmaceuticals

KalVista Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Immunology; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
sebetralstat (KVD900)
Plasma kallikrein inhibitor
KLKB1Phase 4Hereditary AngioedemaNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07654829sebetralstat (KVD900)Phase 4Hereditary AngioedemaImmunologyNov 2027

Targets

KLKB1 (1)

Companies with the same targets

Kyowa Kirin BioCryst Pharmaceuticals ADARx Pharmaceuticals Pharvaris Netherlands DiaMedica Therapeutics

Companies built like this

Pharvaris Netherlands BioCryst Pharmaceuticals Biopharma Plasma Psoriasis Research Institute of Guangzhou Triple Hair

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.